Jensen, Lars Henrik

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 3,099

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

André, T., Elez, E., Van Cutsem, E., Jensen, L. H., Bennouna, J., Mendez, G., Schenker, M., de la Fouchardiere, C., Limon, M. L., Yoshino, T., et al. (2024) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 286

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): A randomised, open-label, phase 3 trial

André, T., Elez, E., Lenz, H.-J., Jensen, L. H., Touchefeu, Y., Van Cutsem, E., Garcia-Carbonero, R., Tougeron, D., Mendez, G. A., Schenker, M., et al. (2025) · The Lancet

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 256

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): An open-label, randomised, phase 3 trial

Andre, T., Amonkar, M., Norquist, J. M., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D., Garcia-Carbonero, R., et al. (2021) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 209

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study

Andre, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D. M., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 194

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study

Andre, T., Elez, E., Van Cutsem, E., Jensen, L. H., Bennouna, J., Mendez, G., Schenker, M., De La Fouchardiere, C., Limon, M. L., Yoshino, T., et al. (2024) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 63

KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer

Shiu, K.-K., Andre, T., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D. M., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2021) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 59

First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.

Andre, T., Elez, E., Lenz, H.-J., Jensen, L. H., Touchefeu, Y., Van Cutsem, E., Garcia-Carbonero, R., Tougeron, D., Mendez, G., Schenker, M., et al. (2025) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 9